Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

[1]  Jason G. Jin,et al.  Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing , 2014, Nature Communications.

[2]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[3]  Lirong Pei,et al.  Abstract 4012: Large-scale characterization of DNA methylation changes in human gastric carcinomas with and without metastasis , 2014 .

[4]  Shibing Deng,et al.  Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer , 2014, Nature Genetics.

[5]  Atsushi Tanaka,et al.  Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma , 2014, Nature Genetics.

[6]  Thomas D. Wu,et al.  Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer , 2014, Nature Communications.

[7]  Insuk Sohn,et al.  Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery , 2014, PloS one.

[8]  S. Cykert.  A New Paradigm. , 2014, Chest.

[9]  Andreas Schlicker,et al.  Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition , 2013, International journal of cancer.

[10]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[11]  Bin Tean Teh,et al.  Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. , 2013, Gastroenterology.

[12]  N. Hu,et al.  Comparison of Global Gene Expression of Gastric Cardia and Noncardia Cancers from a High-Risk Population in China , 2013, PloS one.

[13]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[14]  Tianhong Li,et al.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Kokot,et al.  Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. , 2013, Head & neck oncology.

[16]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[17]  A. McCullough.  Comprehensive molecular characterization of human colon and rectal cancer , 2013 .

[18]  B. Teh,et al.  Methylation Subtypes and Large-Scale Epigenetic Alterations in Gastric Cancer , 2012, Science Translational Medicine.

[19]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[20]  Bauke Ylstra,et al.  Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer , 2012, Gut.

[21]  M. Vijver,et al.  HER2 testing in gastric cancer: a practical approach , 2012, Modern Pathology.

[22]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[23]  Khay Guan Yeoh,et al.  A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets , 2012, Gut.

[24]  Y. Bang,et al.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.

[25]  Joon-Oh Park,et al.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Baselga,et al.  Targeted therapies for breast cancer. , 2011, The Journal of clinical investigation.

[27]  Chia Huey Ooi,et al.  Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. , 2011, Gastroenterology.

[28]  T. Yeatman,et al.  Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. , 2011, The American journal of pathology.

[29]  Jae Yong Cho,et al.  Gene Expression Signature–Based Prognostic Risk Score in Gastric Cancer , 2011, Clinical Cancer Research.

[30]  Laura H. Tang,et al.  Molecular Classification of Gastric Cancer: A New Paradigm , 2011, Clinical Cancer Research.

[31]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[32]  L. V. van't Veer,et al.  Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  David B Jackson,et al.  EMT is the dominant program in human colon cancer , 2011, BMC Medical Genomics.

[34]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[35]  Ramnik J. Xavier,et al.  Gene enrichment profiles reveal T-cell development, differentiation, and lineage-specific transcription factors including ZBTB25 as a novel NF-AT repressor. , 2010, Blood.

[36]  C. Park,et al.  Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. , 2010, Gastroenterology.

[37]  S. Swamy,et al.  PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data , 2009, Biostatistics.

[38]  Hyun Cheol Chung,et al.  Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer , 2009, PLoS genetics.

[39]  J. Heo,et al.  Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Joon-Oh Park,et al.  An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. , 2005, International journal of radiation oncology, biology, physics.

[41]  Yudong D. He,et al.  A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. , 2005, Cancer research.

[42]  J. Ajani,et al.  Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  D. Botstein,et al.  Variation in gene expression patterns in human gastric cancers. , 2003, Molecular biology of the cell.

[44]  B. Leggett,et al.  The impact of microsatellite instability on the molecular phenotype of colorectal tumors. , 2003, Cancer research.

[45]  Siew Hong Leong,et al.  A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. , 2003, Cancer research.

[46]  A. Duval,et al.  Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. , 2002, Gastroenterology.

[47]  N. Matsubara,et al.  Instabilotyping reveals unique mutational spectra in microsatellite-unstable gastric cancers. , 2002, Cancer research.

[48]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[50]  R. Wallace.  Is this a practical approach? , 2001, Journal of the American College of Surgeons.

[51]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[52]  I. Jolliffe.  Principal Component Analysis , 2005 .